Response Factors to Pegylated Interferon-Alfa/Ribavirin Treatment in Chronic Hepatitis C Patients Genotype 1b
AuthorsJovanović-Ćupić, Snežana P.
Božović, Ana M.
Dimitrijević, Bogomir B.
MetadataShow full item record
Hepatitis C virus infection is the most common chronic blood-borne infection and one of the most important causes of chronic liver disease. Knowing the predictors associated with pegylated interferon/ribavirin (PEG-IFN/RBV) combination therapy response is important for evidence-based treatment recommendations. The goal of this study was to identify host and viral factors of response to PEG-IFN/RBV treatment in chronic hepatitis C genotype 1b patients. We have examined the relationship between gender, age, level of alanine aminotransferase (ALT), viral load and liver fibrosis progression on therapy response. ALT level and viral load were evaluated before starting treatment with combination therapy. The elevated levels of ALT and route of HCV transmission were found to be significantly associated with the response to therapy in HCV-infected patients. Our findings may be useful for estimating a patients likelihood Of achieving sustained viral response.